Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study

Background: Talazoparib is a poly(ADP-ribose) polymerase enzyme inhibitor. This open-label, non-randomized, phase 1 study of talazoparib investigated the safety, pharmacokinetics, and preliminary antitumor activity in Japanese patients with locally advanced or metastatic solid tumors, regardless of...

Descripción completa

Detalles Bibliográficos
Autores principales: Naito, Yoichi, Kuboki, Yasutoshi, Ikeda, Masafumi, Harano, Kenichi, Matsubara, Nobuaki, Toyoizumi, Shigeyuki, Mori, Yuko, Hori, Natsuki, Nagasawa, Takashi, Kogawa, Takahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541992/
https://www.ncbi.nlm.nih.gov/pubmed/34160752
http://dx.doi.org/10.1007/s10637-021-01120-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541992/
https://www.ncbi.nlm.nih.gov/pubmed/34160752
http://dx.doi.org/10.1007/s10637-021-01120-7

Ejemplares similares